Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial-Reference-Cited by-同舟云学术

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Published:2018-03-01 Issue:3 Volume:4 Page:302
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Gianni Luca¹,Mansutti Mauro²,Anton Antonio³,Calvo Lourdes⁴,Bisagni Giancarlo⁵,Bermejo Begoña⁶,Semiglazov Vladimir⁷,Thill Marc⁸,Chacon Jose Ignacio⁹,Chan Arlene¹⁰,Morales Serafin¹¹,Alvarez Isabel¹²,Plazaola Arrate¹³,Zambetti Milvia¹,Redfern Andrew D.¹⁴,Dittrich Christian¹⁵,Dent Rebecca Alexandra¹⁶,Magazzù Domenico¹⁷,De Fato Raffaella¹⁷,Valagussa Pinuccia¹⁷,Tusquets Ignacio¹⁸

Affiliation:

1. Department of Medical Oncology, San Raffaele Scientific Institute, Milano, Italy

2. Department of Oncology, Azienda Sanitaria Universitaria Integrata, Udine, Italy

3. Department of Medical Oncology, Miguel Servet University Hospital, Aragón Health Research Institute, Zaragoza, Spain

4. Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

5. IRCCS Arcispedale Santa Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy

6. Department of Medical Oncology, Hospital Clinico Universitario Valencia, Valencia, Spain

7. NN Petrov Research Institute of Oncology, St Petersburg, Russia

8. Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, Germany

9. Department of Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain

10. Breast Cancer Research Centre, Western Australia & Curtin University, Perth, Australia

11. Department of Medical Oncology, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain

12. Department of Oncology, Hospital Universitario Donostia, San Sebastian, Spain

13. Onkologikoa, Hospital Donostia, San Sebastián, Spain

14. Department of Medical Oncology, Royal Perth Hospital, Perth, Australia

15. Applied Cancer Research–Institution for Translational Research Vienna (ACR-ITR VIEnna) & Kaiser Franz Josef-Spital, Vienna, Austria

16. Department of Medical Oncology, National Cancer Center Singapore, Singapore

17. Fondazione Michelangelo, Milano, Italy

18. Department of Medical Oncology, Hospital del Mar, Barcelona, Spain

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in clinical application of nanoparticle-based therapy for cancer treatment: A systematic review;Nano TransMed;2024-12

2. Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy;Acta Pharmaceutica Sinica B;2024-09

3. Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study;Frontiers in Oncology;2024-08-21

4. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

5. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies;JCO Oncology Practice;2024-08